*Press releases are taken from the company websites.
*Titles may be translated independently.
*Please be aware that, since data is collected automatically, there is a possibility of omissions occurring.
*We would like to kindly inform you that we do not collect all press releases from companies.
| Ticker Code | Date | Title | Link |
|---|---|---|---|
| TSE:4578 | 12/13/2025 | Results of Phase III STAR-221 study of anti-TIGIT antibody domvanalimab in combination with anti-PD-1 antibody zimberelimab | https://www.taiho.co.jp/release/2025/20251213.html |
| TSE:4540 | 12/12/2025 | New release of “Tsumura’s Wakan Plus Ginéllia” | https://www.tsumura.co.jp/newsroom/newsrelease/item/20251212.pdf |
| TSE:4568 | 12/12/2025 | Daiichi Sankyo's DXd ADC technology wins "Best ADC Platform Technology" | https://www.daiichisankyo.co.jp/news/detail/index_7365.html |
| MRK | 12/12/2025 | Merck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIR™ (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension) | https://www.merck.com/news/merck-receives-positive-eu-chmp-opinion-for-expanded-use-of-winrevair-sotatercept-in-adults-with-pulmonary-arterial-hypertension-pah-who-group-1-pulmonary-hypertension/ |
| PFE | 12/12/2025 | Pfizer Declares First-Quarter 2026 Dividend | https://www.pfizer.com/news/press-release/press-release-detail/pfizer-declares-first-quarter-2026-dividend |
| TSE:4151 | 12/11/2025 | Notice regarding management structure change (CEO change) (145KB) | https://www.kyowakirin.co.jp/pressroom/news_releases/2025/pdf/20251211_01.pdf |
| TSE:4507 | 12/11/2025 | Selected as an "A-list company" by CDP, the highest rating in both "climate change" and "water security" fields | https://www.shionogi.com/jp/ja/news/2025/12/20251211.html |
| TSE:4528 | 12/11/2025 | Selected for the highest rating A list in CDP 2025 “climate change” and “water security” | https://www.ono-pharma.com/ja/news/20251211.html |
| TSE:4568 | 12/11/2025 | About the 18th Manpei Suzuki Diabetes International Award and the 19th Manpei Suzuki Diabetes National Award | https://www.daiichisankyo.co.jp/sustainability/performance-reports/news/detail/index_7364.html |
| TSE:4901 | 12/11/2025 | Selected as “Municipal Government Counter DXSaaS Provider (Recruited in 2020)” (Fujifilm Business Innovation) | https://www.fujifilm.com/fb/company/news/release/2025/83782 |
| TSE:4901 | 12/11/2025 | New release of software "EW10-US01" that detects areas suspected of pancreatic solid lesions (Fujifilm) | https://www.fujifilm.com/jp/ja/news/list/13190 |
| BMY | 12/11/2025 | U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma | https://news.bms.com/news/corporate-financial/2025/U-S--Food-and-Drug-Administration-FDA-Grants-Priority-Review-to-Bristol-Myers-Squibbs-Application-for-Opdivo-nivolumab-Plus-Chemotherapy-Combination-for-Classical-Hodgkin-Lymphoma/default.aspx |
| AMGN | 12/11/2025 | FDA APPROVES UPLIZNA® FOR ADULTS WITH GENERALIZED MYASTHENIA GRAVIS | https://www.amgen.com/newsroom/press-releases/2025/12/fda-approves-uplizna-for-adults-with-generalized-myasthenia-gravis |
| TSE:4534 | 12/10/2025 | Notice of personnel changes | https://ssl4.eir-parts.net/doc/4534/tdnet/2729489/00.pdf |
| TSE:4568 | 12/10/2025 | Regarding the initiation of a phase 3 clinical trial of trastuzumab deruxtecan (T-DXd/DS-8201) as primary maintenance therapy for HER2-expressing ovarian cancer (244.2KB), the PDF file will be displayed in a new window. | https://www.daiichisankyo.co.jp/files/news/pressrelease/pdf/202512/20251210_J.pdf |